NCT01707160View on ClinicalTrials.gov

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 1995

Primary Completion Date

December 31, 1995

Study Completion Date

December 31, 1995

Conditions
DiabetesHealthy
Interventions
DRUG

biphasic insulin aspart 30

One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order

DRUG

biphasic human insulin 30

One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order

Trial Locations (1)

LS2 9NG

Novo Nordisk Investigational Site, Leeds

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY